Medical News

RSS

Renal denervation leads to better outcomes than standard drug treatment in patients with AHF

Renal denervation leads to better outcomes than standard drug treatment in patients with advanced heart failure, according to research presented at ESC Congress 2012. The results of the Olomouc I pilot study were presented by Dr Miloš Táborský from the University Hospital Olomouc.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Bode launches Rapid DNA Service to provide near real-time analysis

The Bode Technology Group, Inc. (Bode), a leading provider of innovative forensic DNA services, announced today the launch of their Rapid DNA Service to provide near real-time DNA analysis.

27 Aug 2012

BD announces acquisition of Sirigen

BD, a leading global medical technology company, announced today that it has acquired Sirigen Group Limited, a developer of unique polymer dyes that are used in flow cytometry and can be applied to other technologies.

From BD (Becton, Dickinson and Company) 27 Aug 2012

Taiwan approves RBC Life Sciences' Stem-Kine for importation and sale

RBC Life Sciences, Inc. announced today that the Company's stem cell supplement, Stem-Kine, has been approved for importation and sale in Taiwan. Stem-Kine is marketed in Taiwan under the name SK Plus.

27 Aug 2012

Update on Merck's development programs for vorapaxar, ER niacin/laropirprant and anacetrapib

Merck today provided an update on the development programs for vorapaxar, extended release niacin/laropirprant (MK524A, Tredaptive) and anacetrapib in association with the European Society of Cardiology (ESC) meeting in Munich.

27 Aug 2012

Healthy foods consumed more often by the wealthy than poor

Healthy foods such as fruits and vegetables, proteins and non-saturated fats are consumed more often by the wealthy while poorer people consume more carbohydrates, concludes a new study involving people from 17 countries.

27 Aug 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012

Lunch boxes and school eating areas are hotspots for bacteria

Canadian moms earn top marks when it comes to good hygiene practices, but a new study by Lysol and the Global Hygiene Council reveals they could do more to safeguard against bacteria hotspots in schools, especially at lunch time.

27 Aug 2012

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, were nearly as effective as when administered as IV injections in terms of reduction in lung viral load.

27 Aug 2012

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

New method helps engineer tissues with embedded nanoscale networks

A multi-institutional research team has developed a method for embedding networks of biocompatible nanoscale wires within engineered tissues. These networks—which mark the first time that electronics and tissue have been truly merged in 3D—allow direct tissue sensing and potentially stimulation, a potential boon for development of engineered tissues that incorporate capabilities for monitoring and stimulation, and of devices for screening new drugs.

27 Aug 2012

CardioDx completes two-tranche equity financing

CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced the completion of a $58 million two-tranche equity financing.

27 Aug 2012

Study explores gender-related differences in patients hospitalized for acute heart failure

Women with acute heart failure have similar in-hospital mortality to men but are less treated in the real world, according to results from the global ALARM-HF registry presented today at the ESC Congress 2012. The findings were presented by Dr John T. Parissis from Greece.

27 Aug 2012

Regulating microbes could help prevent diseases associated with obesity

Vaccines and antibiotics may someday join caloric restriction or bariatric surgery as a way to regulate weight gain, according to a new study focused on the interactions between diet, the bacteria that live in the bowel, and the immune system.

27 Aug 2012

Spironolactone should be considered as a treatment option in hypertensive patients with DHF

Mineralocorticoid receptor antagonists should be considered as a treatment option in hypertensive patients with diastolic heart failure, said Professor Burkert Pieske presenting results today of the Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) study at ESC Congress 2012.

27 Aug 2012